{"id":784523,"date":"2023-09-18T09:20:28","date_gmt":"2023-09-18T13:20:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/"},"modified":"2023-09-18T09:20:28","modified_gmt":"2023-09-18T13:20:28","slug":"catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/","title":{"rendered":"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference"},"content":{"rendered":"
\n

CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the Catalyst\u2019s senior management team, will\u00a0participate in the 2023 Cantor Global Healthcare Conference which will be held on September 26-28, 2023.<\/p>\n

\n Presentation Details:<\/strong>\n <\/p>\n

\n Event<\/strong>: 2023 Cantor Global Healthcare Conference
Date<\/strong>: September 26, 2023
Time<\/strong>: 11:05 A.M. ET
Webcast Link<\/strong>: https:\/\/wsw.com\/webcast\/cantor19\/cprx\/2116653<\/a><\/p>\n

The webcast of the presentation will be available on the\u00a0Company’s website<\/a>, and a replay will be accessible for at least 14 days.<\/p>\n

\n About Catalyst Pharmaceuticals<\/strong>
\n
With exceptional patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases. Catalyst\u2019s\u00a0flagship U.S.\u00a0commercial product is FIRDAPSE\u00ae<\/sup>\u00a0(amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”) for adults and for children ages six to seventeen. In\u00a0January 2023, Catalyst acquired the\u00a0U.S.\u00a0commercial rights to FYCOMPA\u00ae<\/sup>\u00a0(perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older. Further,\u00a0Canada\u2019s\u00a0national healthcare regulatory agency,\u00a0Health Canada, has approved the use of FIRDAPSE\u00a0for the treatment of adult patients in\u00a0Canada\u00a0with LEMS. Finally, on\u00a0July 18, 2023, Catalyst acquired an exclusive license for\u00a0North America\u00a0for vamorolone, a promising best-in-class dissociative anti-inflammatory steroid treatment for Duchenne Muscular Dystrophy.\u00a0Vamorolone has received FDA Orphan Drug and Fast Track designations and has been granted a PDUFA action date of\u00a0October 26, 2023.<\/p>\n

For more information about\u00a0Catalyst Pharmaceuticals, Inc., visit the Company\u2019s website at\u00a0www.catalystpharma.com<\/a>. For the Full Prescribing and Safety Information for FIRDAPSE\u00ae<\/sup>, please visit\u00a0www.firdapse.com<\/a>. For the Full Prescribing Information for FYCOMPA\u00ae<\/sup>, please visit\u00a0www.fycompa.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2022 and its other filings with the\u00a0U.S. Securities and Exchange Commission\u00a0(\u201cSEC\u201d), could adversely affect Catalyst. Copies of Catalyst’s filings with the\u00a0SEC\u00a0are available from the\u00a0SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.<\/p>\n

Source: Catalyst Pharmaceuticals<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

\n
Investor Relations Contact:\r\nMary Coleman\r\nCatalyst Pharmaceuticals\r\n(305) 420-3200\r\nmcoleman@catalystpharma.com\r\n\r\nMedia Contact:\r\nDavid Schull\r\nRusso Partners\r\n(858) 717-2310\r\ndavid.schull@russopartnersllc.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the Catalyst\u2019s senior management team, will\u00a0participate in the 2023 Cantor Global Healthcare Conference which will be held on September 26-28, 2023. Presentation Details: Event: 2023 Cantor Global Healthcare ConferenceDate: September 26, 2023Time: 11:05 A.M. ETWebcast Link: https:\/\/wsw.com\/webcast\/cantor19\/cprx\/2116653 The webcast of the presentation will be available on the\u00a0Company’s website, and a replay will be accessible for at least 14 days. About Catalyst Pharmaceuticals With exceptional patient focus, Catalyst is committed to developing … <\/p>\n
Continue reading “Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-784523","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCatalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the Catalyst\u2019s senior management team, will\u00a0participate in the 2023 Cantor Global Healthcare Conference which will be held on September 26-28, 2023. Presentation Details: Event: 2023 Cantor Global Healthcare ConferenceDate: September 26, 2023Time: 11:05 A.M. ETWebcast Link: https:\/\/wsw.com\/webcast\/cantor19\/cprx\/2116653 The webcast of the presentation will be available on the\u00a0Company’s website, and a replay will be accessible for at least 14 days. About Catalyst Pharmaceuticals With exceptional patient focus, Catalyst is committed to developing … Continue reading "Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-18T13:20:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference\",\"datePublished\":\"2023-09-18T13:20:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/\"},\"wordCount\":459,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/\",\"name\":\"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE=\",\"datePublished\":\"2023-09-18T13:20:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference - Market Newsdesk","og_description":"CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the Catalyst\u2019s senior management team, will\u00a0participate in the 2023 Cantor Global Healthcare Conference which will be held on September 26-28, 2023. Presentation Details: Event: 2023 Cantor Global Healthcare ConferenceDate: September 26, 2023Time: 11:05 A.M. ETWebcast Link: https:\/\/wsw.com\/webcast\/cantor19\/cprx\/2116653 The webcast of the presentation will be available on the\u00a0Company’s website, and a replay will be accessible for at least 14 days. About Catalyst Pharmaceuticals With exceptional patient focus, Catalyst is committed to developing … Continue reading \"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-18T13:20:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference","datePublished":"2023-09-18T13:20:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/"},"wordCount":459,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/","name":"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE=","datePublished":"2023-09-18T13:20:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMzMxNCM1ODE3NjgzIzIwMTk0OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/784523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=784523"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/784523\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=784523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=784523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=784523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}